Preclinical and innovative uses of anticocaine vaccine: the UFMG-V4N2
Abstract: The most promising strategy for treating cocaine addiction is an anti-cocaine vaccine. The treatment is based on the production of anti-cocaine antibodies, which blocks cocaine passage through the blood-brain barrier. The blockage results in the preclusion or reduction of activity in the reward system, limiting the psychotropic effects of the drug. Our research group developed a new vaccine candidate, the UFMG-V4N2 and innovative uses of the anticocaine vaccine. In this presentation we will present the preclinical track followed by our research group to reach the regulatory approval for human use of the UFMG-VAC-V4N2 and discuss the results yield from the new applications of the anticocaine vaccine.